Keyword: Lars Rebien Sorensen
A fight has emerged between countries vying for the economic lift and status that come with hosting the EMA.
Someone entirely new at Novo Nordisk will have to deal with big challenges in its largest market after its head of North American operations quit.
Novo Nordisk is taking the price-increase pledge. Three months after Allergan CEO Brent Saunders surprised pharma with a similar vow, Novo says it will limit list-price hikes to single-digit percentages annually.
On its annual list of the world’s 100 top CEOs, Harvard Business Review tagged 5 biopharma execs--and one, Novo Nordisk CEO Lars Rebien Sørensen, took the No. 1 slot for the second year in a row. Thing is, two of those 5 are on their way out.
Novo Nordisk, pressured by U.S. payers and stepped-up competition in its signature diabetes market, will lay off 1,000 people worldwide to cut costs and sharpen its focus on “truly innovative” new products.
The man who last year topped Harvard Business Review’s “world’s best-performing CEO” ranking will be stepping down from Danish diabetes company Novo Nordisk after 16 years on the job.
